NCT05238922 - Study of INCB123667 in Subjects With Advanced Solid Tumors | Biotech Hunter

Enrollment

604

Participants

Timeline

Start Date

July 5, 2022

Primary Completion Date

July 27, 2027

Study Completion Date

August 31, 2027

Conditions

Solid Tumors

Interventions

DRUG

INCB0123667

25 mg tablets

DRUG

Palbociclib

Palbociclib will be administered at protocol defined dose.

DRUG

Bevacizumab

Bevacizumab will be administered at protocol defined dose.

DRUG

Olaparib

Olaparib will be administered at protocol defined dose.

DRUG

Paclitaxel

Paclitaxel will be administered at protocol defined dose.

DRUG

Ribociclib

Ribociclib will be administered at protocol defined dose.

DRUG

Fulvestrant

Fulvestrant will be administered at protocol defined dose.

Trial Locations (43)

3010

RECRUITING

Inselspital Universitatsklinik Fur Medizinische Onkologie, Bern

6500

RECRUITING

Oncological Institute of Southern Switzerland, Bellinzona

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

RECRUITING

New York Presbyterian/Weill Cornell, New York

11967

NOT_YET_RECRUITING

Ny Cancer and Blood Specialists, Shirley

15213

RECRUITING

University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh

15224

NOT_YET_RECRUITING

Allegheny Health Network, Pittsburgh

19104

RECRUITING

University of Pennsylvania Abramson Cancer Center, Philadelphia

20089

RECRUITING

Irccs Istituto Clinico Humanitas, Rozzano

20133

RECRUITING

Fondazione Irccs Istituto Nazionale Dei Tumori, Milan

22031

NOT_YET_RECRUITING

Virginia Cancer Institute, Fairfax

28078

COMPLETED

Carolina Bio-Oncology Institute, Pllc, Huntersville

30322

RECRUITING

Emory University, Atlanta

31059

RECRUITING

Universitaire Du Cancer de Toulouse Institut Claudius Regaud Iuct-Oncopole, Toulouse

33076

RECRUITING

Institut Bergonie, Bordeaux

33140

RECRUITING

Mount Sinai Medical Center Comprehensive Cancer Center, Miami Beach

37134

RECRUITING

Centro Ricerche Cliniche Di Verona, Verona

37203

NOT_YET_RECRUITING

Tennessee Oncology, Nashville

44195

WITHDRAWN

Cleveland Clinic, Cleveland

53792

NOT_YET_RECRUITING

University of Wisconsin, Madison

69373

RECRUITING

Centre Leon Berard, Lyon

76104

RECRUITING

Texas Oncology-Fort Worth South Henderson, Fort Worth

80124

RECRUITING

Rocky Mountain Cancer Centers-Sky Ridge, Lone Tree

80131

RECRUITING

Istituto Nazionale Tumori Irccs Fondazione Pascale, Naples

90067

NOT_YET_RECRUITING

Valkyrie Clinical Trials, Los Angeles

91010

RECRUITING

City of Hope Medical Center, Duarte

92618

RECRUITING

City of Hope-Lennar Foundation Cancer Center, Irvine

94805

RECRUITING

Institut Gustave Roussy, Villejuif

06510

COMPLETED

Yale Cancer Center, New Haven

07601

NOT_YET_RECRUITING

Hackensack University Medical Center, Hackensack

00168

RECRUITING

Policlinico Universitario Agostino Gemelli Universita Cattolica Del Sacro Cuore, Rome

464-8681

RECRUITING

Aichi Cancer Center Hospital, Aichi

277-8577

RECRUITING

National Cancer Center Hospital East, Chiba

350-1298

RECRUITING

Saitama Medical University International Medical Center, Hidaka-shi

135-8550

RECRUITING

The Cancer Institute Hospital of Jfcr, Kōtoku

104-0045

RECRUITING

National Cancer Center Hospital, Tokyo

1066 CX

RECRUITING

Netherlands Cancer Institute Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam

3015 GD

RECRUITING

Erasmus Medical Center, Rotterdam

00935

RECRUITING

Panoncology Trials Pan American Center For Oncology Trials, Llc, Rio Piedras

01011

RECRUITING

Centre Hospitalier Universitaire Vaudois (Chuv), Lausanne

SE1 9RT

RECRUITING

Guys Hospital, London

W12 0HS

RECRUITING

Imperial College Healthcare Nhs Trust - Hammersmith Hospital, London

NE7 7DN

RECRUITING

Northern Centre For Cancer Care, Newcastle upon Tyne